A2LQV6 KKR & Co Inc

Clinisupplies Acquires Aquaflush TAI Portfolio to Continue Building a Leading Chronic Care Organisation

Clinisupplies Limited (“Clinisupplies”), a leading manufacturer and supplier of continence care consumables, today announced the acquisition of the Aquaflush transanal irrigation (“TAI”) business from Renew Medical Inc. and Renew Medical UK Limited, a US and UK manufacturer of continence products (together “Renew”).

The acquisition of the Aquaflush TAI range will enable Clinisupplies to expand its offering to include bowel management products, while also supporting patients living with chronic bowel issues through its nursing services.

Clinisupplies continues to integrate fast growing businesses, strengthening its position as a leading UK based direct-to-consumer chronic care company, providing continence care products and nursing services that helps support the NHS. Earlier this year, following an investment by funds managed by KKR, Clinisupplies announced the acquisition of Great Bear Healthcare, a UK-based manufacturer and supplier of urinary continence care products for managing acute and chronic conditions in the community.

Paul Cook, CEO at Clinisupplies, commented: “The Aquaflush business is a perfect fit with Clinisupplies’ purpose of helping people with continence issues to live more freely through the products and services we provide. It is our ambition to continue broadening this range of products and services in order to reach more consumers and healthcare professionals and to better support their needs. We are excited to add the Aquaflush range to our portfolio and to continue building on our growing position in the UK and around the world.”

Jason Tate, CEO at Renew, commented: “We have been delighted with the success Renew has enjoyed in recent years, and for the growing number of people who rely on the innovative range of Aquaflush TAI products. We are excited to see the next phase of development for the range and the growing support for Aquaflush users under the team at Clinisupplies.”

KKR invested in Clinisupplies through KKR Health Care Strategic Growth Fund II, a $4.0 billion fund focused on investing in high-growth health care companies. KKR has a long track record of supporting health care companies globally, having invested approximately $19 billion in the sector since 2004.

About Clinisupplies

Clinisupplies is a manufacturer and supplier of medical appliances specialising in continence products for managing acute and chronic conditions. Employing over 500 people in the UK, China and India, Clinisupplies provides its products to the NHS and delivers direct to patients’ homes through Clinidirect, its dispensing appliance contractor.

Clinisupplies is focused on developing products which are simple and discreet to use. Its product development team works with clinicians and patients to develop a strong product pipeline to be manufactured at its CE, ISO, US FDA approved facilities.

Please visit for further information.

About KKR

KKR is a leading global investment firm that offers alternative asset management as well as capital markets and insurance solutions. KKR aims to generate attractive investment returns by following a patient and disciplined investment approach, employing world-class people, and supporting growth in its portfolio companies and communities. KKR sponsors investment funds that invest in private equity, credit and real assets and has strategic partners that manage hedge funds. KKR’s insurance subsidiaries offer retirement, life and reinsurance products under the management of Global Atlantic Financial Group. References to KKR’s investments may include the activities of its sponsored funds and insurance subsidiaries. For additional information about KKR & Co. Inc. (NYSE: KKR), please visit KKR’s website at . For additional information about Global Atlantic Financial Group, please visit Global Atlantic Financial Group’s website at .

EN
26/10/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on KKR & Co Inc

KKR & Co Inc: 1 director

A director at KKR & Co Inc sold 809,906 shares at 144.250USD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly ...

 PRESS RELEASE

KKR Appoints Timothy R. Barakett to Board

NEW YORK--(BUSINESS WIRE)-- KKR & Co. Inc. (NYSE: KKR) today announced that Timothy R. Barakett has been appointed to the Board of Directors effective March 13, 2025. His appointment will bring the number of independent directors to ten out of a total of fourteen Board seats. This press release features multimedia. View the full release here: Timothy R. Barakett (Photo: Business Wire) Mr. Barakett is the Founder and Chief Executive Officer of TRB Advisors, a private investment firm and family office. Prior to founding TRB Advisors in 2010, Mr. Barakett was the Founder and Chief Executive Offic...

 PRESS RELEASE

Darwinbox Raises $140 Million Investment Co-led by Partners Group and ...

HYDERABAD, India--(BUSINESS WIRE)-- , a leading global human resource (“HR”) technology platform, today announced the signing of definitive agreements under which Partners Group, one of the largest firms in the global private markets industry (acting on behalf of its clients), and funds managed by KKR, a leading global investment firm, will co-lead an investment of $140 million in the company, with additional participation from Gravity Holdings. The addition of Partners Group and KKR to an already-solid cap-table underscores Darwinbox’s strong momentum over the recent years. The investment pos...

 PRESS RELEASE

KKR to Sell Seiyu to Trial Holdings

TOKYO--(BUSINESS WIRE)-- KKR, a leading global investment firm, and Seiyu, a nationwide supermarket chain in Japan, today announced the signing of definitive agreements to sell Seiyu (the “Company”) to Trial Holdings, Inc. (TSE stock code 141A; “Trial”), a distribution and retail business operator in Japan that operates a network of stores offering “everyday essentials” in Kyushu. This transaction represents a significant outcome for KKR and follows transformational work that positions Seiyu strongly for continued success. This press release features multimedia. View the full release here: KK...

 PRESS RELEASE

KKR Upsizes and Prices Offering of Mandatory Convertible Preferred Sto...

NEW YORK--(BUSINESS WIRE)-- KKR & Co. Inc. (“KKR”) (NYSE: KKR) today announced that it has priced its previously announced offering of $2.25 billion (45,000,000 shares) of its 6.25% Series D Mandatory Convertible Preferred Stock (the “mandatory convertible preferred stock”) at a price to the public and liquidation preference of $50.00 per share. The offering was upsized from the previously announced size of $1.50 billion (30,000,000 shares). The underwriters have a 30-day option to purchase up to an additional $337.50 million (6,750,000 shares) of mandatory convertible preferred stock, solely ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch